Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Short-term effects of Chlorhexidine mouthwash and Listerine on oral microbiome in hospitalized patients

PROVIDER: PRJNA834608 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19048900_1.fastq.gz	Fastqsanger.gz
	SRR19048900_2.fastq.gz	Fastqsanger.gz
	SRR19049000_1.fastq.gz	Fastqsanger.gz
	SRR19049000_2.fastq.gz	Fastqsanger.gz
	SRR19048901_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 348

Similar Datasets

Project description:Effects of propolis and chlorhexidine mouthwash on the oral microbiome and cardiovascular function

| PRJNA1088292 | ENA

Chlorhexidine and oral microbiome

Project description:The effect of chlorhexidine mouthwash on the the oral microbiome

| PRJEB34404 | ENA

human oral metagenome

Project description:Chlorhexidine-free mouthwash inhibits pathobionts while preserving the oral microbiome

| PRJNA858625 | ENA

Prevention of oral mucositis in pediatric patients with acute lymphoblastic leukemia undergoing chemotherapy: a randomized controlled, cross-over trial using 0.12% chlorhexidine gluconate and 1% povidone iodine mouthwash

Project description:Interventions: Two period cross-over trial. Intervention with mouth-rinsing will commence at the start of either induction, consolidation, or re-induction chemotherapy phase. Group 1 will be rinse with 10 mL of 0.12% chlorhexidine gluconate mouthwash twice daily, and Group 2 will rinse with 15 mL of 1% povidone iodine mouthwash twice daily, for 14 days during the first period of study. Alkaline saline mouthrinse will be used by the subjects during the 2 week ‘washout’ time between the two periods of study. The two groups will then switch mouthrinses during the second study period. The occurrence of ulcerative lesions and severity of mucositis will be measured at baseline and twice weekly of each study period, using the Oral Mucositis Assessment Scale and World Health Organization Grading Scale. If oral mucositis/ulceration develops during either period and persists beyond 14 days, the subjects will continue to use the mouthwash assigned to their group until lesions heal. A participant diary on the use of mouthwash and other oral care hygiene measures such as toothbrushing and flossing will be used to monitor adherence to treatment. Primary outcome(s): determining whether there is a difference in effect of 0.12% chlorhexidine and 1% povidone iodine mouthrinses that are both accepted as standard of care for oral mucositis in pediatric cancer patients using the Oral Mucositis Assessment Scale and World Health Organization Grading Scale[2 weeks] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Open (masking not used);Assignment: Crossover;Type of endpoint: Efficacy

| 2460527 | ecrin-mdr-crc

Project description:Oral microbiome and oral lesion in hospitalized patients with COVID-19

| PRJNA1068049 | ENA

Genomic and Transcriptomic Insights into Chlorhexidine Adaptation in Oral Streptococcus spp.: Implications for Antimicrobial Resistance

Project description:Chlorhexidine (CHX) is a widely used antiseptic agent in dental care due to its broad-spectrum antimicrobial properties. This study focuses on the transcriptomic changes associated with chlorhexidine adaptation in oral Streptococcus salivarius (73_wt, 73_a), Streptococcus vestibularis (78_wt, 78_e), and Streptococcus mitis (93_wt, 93_d) using RNA sequencing.

2024-12-31 | GSE277379 | GEO

Project description:Comparison of oral microbiome in mouthwash and saliva

| PRJNA431300 | ENA

Project description:Oral and gut microbiome signature in hospitalized patients with COVID-19

| PRJNA684070 | ENA

Morphine treatment leads to temporal modulation of the gut microbiome

Project description:Opioid analgesics are frequently prescribed in the United States and worldwide. However, serious side effects such as addiction, immunosuppression and gastrointestinal symptoms limit long term use. In the current study using a chronic morphine-murine model a longitudinal approach was undertaken to investigate the role of morphine modulation of gut microbiome as a mechanism contributing to the negative consequences associated with opioids use. The results revealed a significant shift in the gut microbiome and metabolome within 24 hours following morphine treatment when compared to placebo. Morphine induced gut microbial dysbiosis exhibited distinct characteristic signatures profiles including significant increase in communities associated with pathogenic function, decrease in communities associated with stress tolerance. Collectively, these results reveal opioids-induced distinct alteration of gut microbiome, may contribute to opioids-induced pathogenesis. Therapeutics directed at these targets may prolong the efficacy long term opioid use with fewer side effects.

2018-04-16 | E-MTAB-5550 | biostudies-arrayexpress

Project description:Mouthwash and the oral microbiota

| PRJNA759097 | ENA